Trevi Therapeutics, Inc. is a clinical stage biotechnology company focused on developing Nalbuphine ER for chronic pruritus (itch).

News
Trevi Therapeutics Announces Initiation of a Pivotal Study of Nalbuphine ER in Uremic Pruritus
7/14/2014
Study will enroll 360 patients in the United States and Europe
Trevi Therapeutics Announces $25 Million Series B Financing Led by TPG Biotech for Development of Nalbuphine ER
6/4/2014
Company initiating activities for pivotal trials in chronic pruritic conditions of uremic pruritus and prurigo nodularis